Revefenacin is a muscarinic antagonist used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [1]. Mylan, now known as Viatris, is a company that has been involved with generic versions of medications.
What is the generic name for Revefenacin?
The active pharmaceutical ingredient in Revefenacin is revefenacin [1].
What are the indications for Revefenacin?
Revefenacin is prescribed for adult patients diagnosed with overactive bladder (OAB). This condition is characterized by symptoms such as urge urinary incontinence, urinary urgency, and urinary frequency [1].
How does Revefenacin work?
Revefenacin functions as a muscarinic antagonist. It works by blocking the action of acetylcholine on muscarinic receptors in the bladder detrusor muscle. This blockage inhibits involuntary bladder muscle contractions, thereby reducing the symptoms of OAB [1].
When does the patent for Revefenacin expire?
Information regarding specific patent expiry dates for Revefenacin can be found on resources like DrugPatentWatch.com, which tracks pharmaceutical patent landscapes [2].
Who manufactures generic versions of OAB medications?
Companies like Mylan, which is now part of Viatris, have historically manufactured generic versions of various medications, including those used for overactive bladder. The availability of generic options often follows the expiration of patents for the branded drug [2].
How does Revefenacin compare to other OAB treatments?
Other OAB treatments include different classes of drugs, such as beta-3 adrenergic agonists, and alternative muscarinic antagonists. The choice of treatment typically depends on individual patient factors, including symptom severity, side effect profiles, and medical history. For instance, while some muscarinic antagonists might have a higher risk of certain side effects like dry mouth or constipation, newer agents may offer a different balance of efficacy and tolerability [1].
What are the potential side effects of Revefenacin?
Common side effects associated with muscarinic antagonists like revefenacin can include dry mouth, constipation, blurred vision, and cognitive impairment. The specific side effect profile can vary among individuals [1].
What is the regulatory status of Revefenacin?
Revefenacin has received regulatory approval for the treatment of OAB in relevant markets. The approval process involves rigorous review of clinical trial data demonstrating safety and efficacy [1].
---
Sources
[1] Revefenacin - DrugPatentWatch.com - https://www.drugpatentwatch.com/drug/revefenacin
[2] Drug Patents | DrugPatentWatch - https://www.drugpatentwatch.com/